The US Food and Drug Administration granted the Swiss pharma’s LEE011 (ribociclib) a priority review for treatment of HR+/HER2- advanced breast cancer, meaning a decision is due within six ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback